Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

2024-515827-12-00 Protocol UC02-123-01 Human pharmacology (Phase I) - First administration to humans Ended

Start 28 Jan 2020 · End 11 Apr 2025 · Status Ended · 2 EU/EEA countries · 10 sites · Protocol UC02-123-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 40
Countries 2
Sites 10

Acute Myeloid Leukemia (AML)

Key facts

Sponsor
AvenCell Europe GmbH
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]
Trial duration
28 Jan 2020 → 11 Apr 2025
Decision date (initial)
2024-08-13
Transition trial
Yes
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2024-515827-12-00
EudraCT number
2019-001339-30

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Acute Myeloid Leukemia (AML)

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AvenCell Europe GmbH

Sponsor organisation
AvenCell Europe GmbH
Address
Tatzberg 47, Johannstadt-Nord Johannstadt-Nord
City
Dresden
Postcode
01307
Country
Germany

Scientific contact point

Organisation
AvenCell Europe GmbH
Contact name
Chief Scientific Officer

Public contact point

Organisation
AvenCell Europe GmbH
Contact name
Project Manager

Locations

2 EU/EEA countries · 10 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 35 8
Netherlands Ended 5 2
Rest of world 0

Investigational sites

Germany

8 sites · Ended
Klinikum der Universitaet Muenchen AöR
Medizinische Klinik und Poliklinik III, Marchioninistrasse 15, Hadern, Munich
Universitaetsklinikum Wuerzburg AöR
CCC Mainfranken, Interdisziplinäres Studienzentrum mit ECTU, Straubmuehlweg 2a, Grombuehl, Wuerzburg
University Medical Center Hamburg-Eppendorf
Zentrum für Onkologie Studienzentrale der II. Medizinischen Klinik, Martinistrasse 52, Eppendorf, Hamburg
Universitaetsklinikum Aachen AöR
Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Pauwelsstrasse 30, 52074, Aachen
Philipps-Universitaet Marburg
Klinik für Innere Medizin, Hämatologie, Onkologie, Immunologie, Baldingerstrasse, 35043, Marburg
Universitaet Leipzig
Klinik und Poliklinik für Hämatologie und Zelltherapie, Liebigstrasse 22, Zentrum-Suedost, Leipzig
Universitaetsklinikum Ulm AöR
Innere Medizin III (IM 3), Albert-Einstein-Allee 23, Eselsberg, Ulm
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
Medizinische Klinik und Poliklinik I, Early Clinical Trial Unit, Fetscherstrasse 74, Johannstadt-Nord, Dresden

Netherlands

2 sites · Ended
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Na-823, Secretariaat Hematologie, Dr. Molewaterplein 60, 3015 GJ, Rotterdam
Universitair Medisch Centrum Groningen
dept of Hematology, Hanzeplein 1, 9713 GZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2020-01-28 2020-03-03 2025-02-27
Netherlands 2022-11-02 2024-01-31 2025-02-27

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-04 Germany Acceptable with conditions
2024-08-01
2024-08-02
2 SUBSTANTIAL MODIFICATION SM-2 2024-11-21 Germany Acceptable
2025-01-21
2025-01-21